Table 1. ER+/HER2-low human breast cancer mouse xenograft models and responses to single-agent lumretuzumab and the combination with pertuzumab.

	Tumor growth inhibition
Xenograft (cell line/fragment-based)	Lumretuzumab monotherapy	Combination with pertuzumab
T47D (cell line)	> 100%	n.d.
ZR-75-1 (cell line)	moderate	additive effect
ZR-75-1 (fragment)	100%	n.d.
MCF-7 (cell line)	> 100%	n.d.
MDA-MB-175 (cell line)	47%-100%	complete remission
HBCx-19 (fragment)	100%	complete remission

TGI, tumor growth inhibition; n.d. not done